The present disclosure provides a biosignature that distinguishes Lyme disease, including early Lyme disease, from STARI. The present disclosure also provides methods for detecting Lyme disease and STARI, as well as methods for treating subjects diagnosed with Lyme disease or STARI.

The identification of new biomarkers that are specifically associated with skin dryness. These biomarkers, which are extended synaptotagmin-3 (ESYT3), Ubiquinin-carboxyl terminal hydrolase 7 (USP7), periplakine (PPL) and Late Cornified Envelop Protein 1C (LCE1C), allow for the accurate evaluation of the moisture content of the skin, and particularly allow for the diagnosis of dry skin. Also, a method for determining the moisture content of the skin, and particularly for diagnosing dry skin in a subject, the method including a step of measuring, in a skin sample obtained from the subject, the expression level of at least one protein selected from ESYT3, USP7, PPL and LCE1C. Further, a method for evaluating the efficacy of a cosmetic treatment for hydrating the skin and to a method for screening candidate cosmetic compounds, both being based on measuring the expression level of the above biomarkers.

The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGFβ2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGFβ2-associated diseases, disorders and/or conditions.

The purpose of the present invention is to provide: a method for evaluating various physical conditions accurately; a method for presenting information utilizing the aforementioned method; and a method of screening for a substance capable of improving or preventing physical conditions. A method for evaluating a physical condition of a subject comprises the steps of: determining the value of an abundance of a skin flora, which is collected from the surface of the skin of the subject, on the surface of the skin or the value of a parameter calculated on the basis of the abundance, wherein the reference values for the correlation between the abundance or the parameter with the physical condition has been produced; and then comparing the value with the reference values.

The disclosure relates to methods for treating pemphigus and/or a pemphigoid disease in a subject in need thereof, wherein the methods include administering to a subject in need thereof a therapeutically effective amount of an FcRn inhibitor. In certain embodiments, the FcRn inhibitor is an anti-FcRn antibody or antigen-binding fragment thereof.

Provided are methods of regulating proliferation and/or differentiation of keratinocytes and immune cells, more specifically to methods of treating pathologies characterized by hyperproliferative keratinocytes or inflammatory skin diseases by administration of FABP4-inhibitor.

The present disclosure provides compositions and methods related to the generation and use of transgenic animal models having stem cell reporter systems. In particular, the present disclosure provides a novel transgenic animal model that expresses a nuclear-localized fluorescent reporter in cells endogenously expressing a leucine-rich repeat-containing G-protein coupled receptor (LGR) gene (e.g., LGR5gene). Given the role of LGR genes in stem cell and cancer biology, the transgenic animal models provided herein are useful for a wide range of therapeutic and diagnostic purposes.

Embodiments of the present invention relate to a combination of experimental and computational workflows that allow characterization of skin and subcutaneous tissue microbial flora and its associated metabolome, aiming to first evaluate an individual's skin and subcutaneous tissue to determine if any skin condition is as a result of an imbalance or absence of commensal or mutualistic microorganisms or their associated metabolites. In particular, embodiments of the methods and the associated computational platform provided herein relate to conducting a customized or personalized test and obtaining customized or personalized information regarding the skin and subcutaneous tissue flora and its associated metabolome there from. This may be accomplished by simultaneously identifying hundreds of microorganisms or metabolites on an individual's skin and subcutaneous tissue and comparing the resulting profile to a previously compiled healthy profile from our database of skin profiles. An individual's profile provides the basis of a proprietary probiotic skin care product and personal care products that either maintains a health profile or shifts the individual's skin and subcutaneous tissue flora or its associated metabolome close to a healthy profile, at the same time enhancing the synergies between the microbial flora and host's immune system.

The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGFβ2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGFβ2-associated diseases, disorders and/or conditions.

The disclosure relates to composition and methods to treat dermatological diseases and disorders and to composition useful for treating acne.